Sinovac releases first vaccine trial data on seniors

Sinovac vaccines induced neutralizing antibody responses to live novel coronavirus in adults aged 60 and above, according to the results from the Phase-I and Phase-II clinical trials. All adverse reactions observed among elderly groups were of mild or moderate severity. Graphic: Feng Qingyin/GT